Skip to main content
Home > Week in Review > Clinical Status

Chronological Index of : Clinical Status

 Current Issue
  • Algenpantucel-L: Phase III ongoing

    NewLink Genetics Corp. (NASDAQ:NLNK), Ames, Iowa Product: Algenpantucel-L (HyperAcute Pancreas) Business: Cancer Molecular target: NA Description: Allogeneic cancer vaccine containing irradiated pancreatic tumor cells …

    Published on 5/18/2015
  • AQX-1125: Completed Phase II enrollment

    Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP), Vancouver, B.C. Product: AQX-1125 Business: Dermatology Molecular target: SH2-containing inositol 5-phosphatase (SHIP) Description: SH2-containing inositol 5-phosphatase (SHIP…

    Published on 5/18/2015
  • AuriPro: Completed Phase II enrollment

    Otonomy Inc. (NASDAQ:OTIC), San Diego, Calif. Product: AuriPro (formerly OTO-201) Business: Infectious Molecular target: DNA gyrase Description: Sustained-release gel formulation of ciprofloxacin Indication: Treat acute…

    Published on 5/18/2015
  • Basalog biosimilar insulin glargine: Completed Phase III enrollment

    Biocon Ltd. (NSE:BIOCON; BSE:BIOCON), Bangalore, India Mylan N.V. (NASDAQ:MYL), Canonsburg, Pa. Product: Basalog biosimilar insulin glargine Business: Endocrine/Metabolic Molecular target: NA Description: Biosimilar …

    Published on 5/18/2015
  • Cannabidivarin: Phase II started

    GW Pharmaceuticals plc (LSE:GWP; NASDAQ:GWPH), Salisbury, U.K. Otsuka Pharmaceutical Co. Ltd., Tokyo, Japan Product: Cannabidivarin (CBDV) (GWP42006) Business: Neurology Molecular target: Cannabinoid receptors …

    Published on 5/18/2015
  • CM-24: Phase I started

    cCAM Biotherapeutics Ltd., Misgav, Israel Product: CM-24 Business: Cancer Molecular target: Carcinoembryonic antigen (CEA)-related cell adhesion molecule 1 (CEACAM1) (CD66a) Description: Humanized IgG4 mAb targeting …

    Published on 5/18/2015
  • Dolutegravir: Phase III started

    ViiV Healthcare Ltd., Brentford, U.K. Product: Dolutegravir (Tivicay) Business: Infectious Molecular target: HIV integrase Description: HIV integrase inhibitor Indication: Treat HIV-1 infection Endpoint: Proportion of …

    Published on 5/18/2015
  • Edurant rilpivirine: Phase III started

    Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Product: Edurant rilpivirine (TMC278) Business: Infectious Molecular target: DNA polymerase Description: Diarylpyrimidine non-nucleoside reverse transcriptase inhibitor…

    Published on 5/18/2015
  • FX006: Phase II started

    Flexion Therapeutics Inc. (NASDAQ:FLXN), Burlington, Mass. Product: FX006 Business: Autoimmune Molecular target: NA Description: Sustained-release intra-articular formulation of triamcinolone acetonide (TCA) Indication:…

    Published on 5/18/2015
  • Ibudilast: Completed Phase II enrollment

    MediciNova Inc. (NASDAQ:MNOV; JASDAQ:4875), San Diego, Calif. Kyorin Pharmaceutical Co. Ltd. (Tokyo:4569), Tokyo, Japan Product: Ibudilast (MN-166, AV411) Business: Autoimmune Molecular target: Phosphodiesterase-4 (PDE-…

    Published on 5/18/2015
  • MM-141: Phase II started

    Merrimack Pharmaceuticals Inc. (NASDAQ:MACK), Cambridge, Mass. Product: MM-141 Business: Cancer Molecular target: Epidermal growth factor receptor 3 (EGFR3) (HER3) (ErbB3); Insulin-like growth factor-1 (IGF-1) receptor…

    Published on 5/18/2015
  • P-1037: Phase II started

    Parion Sciences Inc., Durham, N.C. Product: P-1037, GS-5737 Business: Pulmonary Molecular target: Epithelial sodium channel (ENaC) Description: Small molecule epithelial sodium channel (ENaC) inhibitor Indication: Treat…

    Published on 5/18/2015
  • PA-824: Phase III started

    Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Global Alliance for TB Drug Development, New York, N.Y. Product: PA-824 Business: Infectious Molecular target: NA Description: Nitroimidazopyran with activity against…

    Published on 5/18/2015
  • PRO 140: Phase III start

    CytoDyn Inc. (OTCBB:CYDY), Vancouver, Wash. Product: PRO 140 Business: Infectious Molecular target: CC chemokine receptor 5 (CCR5) (CD195) Description: Humanized mAb against CC chemokine receptor 5 (CCR5; CD195) …

    Published on 5/18/2015
  • Viagenpumatucel-L: Phase Ib started

    Heat Biologics Inc. (NASDAQ:HTBX), Chapel Hill, N.C. Product: Viagenpumatucel-L (HS-110) Business: Cancer Molecular target: Heat shock 90 kDa protein beta 1 (Hsp90B1) (GP96) (GRP94) Description: Vaccine comprising lung …

    Published on 5/18/2015
  • Ad-IL-12: Phase I started

    Intrexon Corp. (NYSE:XON), Germantown, Md. Ziopharm Oncology Inc. (NASDAQ:ZIOP), Boston, Mass. Product: Ad-IL-12 (Ad-RTS-IL-12) (ZIN ATI-001) (formerly INXN-2001) Business: Cancer Molecular target: Interleukin-12 (IL-12…

    Published on 5/11/2015
  • BAL3833: Phase I started

    Basilea Pharmaceutica AG (SIX:BSLN), Basel, Switzerland The Institute of Cancer Research, London, U.K. Product: BAL3833, CCT3833 Business: Cancer Molecular target: BRAF Description: Inhibitor of multiple RAF proteins, …

    Published on 5/11/2015
  • Burixafor: Phase I/II started

    TaiGen Biopharmaceuticals Holdings Ltd. (GreTai:4157), Taipei, Taiwan Product: Burixafor (TG-0054) Business: Cancer Molecular target: CXC chemokine receptor 4 (CXCR4) (NPY3R) Description: CXC chemokine receptor 4 (CXCR4…

    Published on 5/11/2015
  • CicloMulsion: Phase II started

    NeuroVive Pharmaceutical AB (SSE:NVP), Lund, Sweden Product: CicloMulsion Business: Renal Molecular target: NA Description: Cremophor-free IV cyclosporine formulation Indication: Prevent acute kidney injury (AKI) …

    Published on 5/11/2015
  • Cirara glyburide for injection: Completed Phase II enrollment

    Remedy Pharmaceuticals Inc., New York, N.Y. Product: Cirara glyburide for injection (RP-1127) Business: Neurology Molecular target: ATP-binding cassette sub-family C member 8 (ABCC8) (SUR1) Description: ATP-binding …

    Published on 5/11/2015
  • CPI-1205: Phase I started

    Constellation Pharmaceuticals Inc., Cambridge, Mass. Product: CPI-1205 Business: Cancer Molecular target: Enhancer of zeste homolog 2 (EZH2) Description: Enhancer of zeste homolog 2 (EZH2) inhibitor Indication: Treat …

    Published on 5/11/2015
  • Eltrapuldencel-T: Phase III started

    NeoStem Inc. (NASDAQ:NBS), New York, N.Y. Product: Eltrapuldencel-T (TC-DC) (NBS20) (formerly melapuldencel-T) Business: Cancer Molecular target: NA Description: Autologous dendritic cells loaded with antigen from self-…

    Published on 5/11/2015
  • GC021109: Phase Ib started

    GliaCure Inc., Boston, Mass. Product: GC021109 Business: Neurology Molecular target: NA Description: Small molecule that stimulates phagocytosis and anti-inflammatory actions to reduce pro-inflammatory cytokines …

    Published on 5/11/2015
  • HX-100: Phase I start

    Hydra Biosciences Inc., Cambridge, Mass. Product: HX-100 Business: Neurology Molecular target: Transient receptor potential A1 (TRPA1) Description: Transient receptor potential A1 (TRPA1) inhibitor Indication: Treat …

    Published on 5/11/2015
  • LYC-30937: Phase I started

    Lycera Corp., Ann Arbor, Mich. Product: LYC-30937 Business: Autoimmune Molecular target: NA Description: Oral gut-directed ATPase modulator Indication: Treat inflammatory bowel disease (IBD) Endpoint: Safety Status: …

    Published on 5/11/2015

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993